preCARDIA, Inc launched new catheter-based system for treating volume overload in patients with acutely decompensated heart failure.
The preCARDIA system, quickly reduces the congestion in the venous system, known as cardiac preload and thus improves the patients overall cardio-renal function. Some of the benefits associated with this novel device is that it reduces re-hospitalisations, improves response in medical management and improves patients quality of life.
Much of the people in US among them older people around 65 of age are admitted to hospitals due to Acute Decompensated HF (ADHF). Despite the availability of pharmacotherapy and device-based heart failure treatments the mortality rates reaches 30 per cent annually. All current therapeutic approaches are palliative, alleviating some symptoms, however ADHF patients continue to have poor morbidity and mortality outcomes. Thus, the need for novel therapies such as catheter-based system was discovered in order to ensure effective and efficient cardio-renal volume unloading in the ADHF patient population.
U.S. Food and Drug Administration (FDA) approval for the novel preCARDIA's technology provides potential benefits and rapid access for patients.
